Top

Published in:

Open Access 01-01-2008 | Preclinical Study

Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer

Authors: Petra van der Groep, Michael Hoelzel, Horst Buerger, Hans Joenje, Johan P. de Winter, Paul J. van Diest

Published in: Breast Cancer Research and Treatment | Issue 1/2008

Abstract

Fanconi anemia (FA) is a recessive disorder associated with progressive pancytopenia, multiple developmental defects, and marked predisposition to malignancies. FA is genetically heterogeneous, comprising at least 12 complementation groups (A–M). Activation of one of the FA proteins (FANCD2) by mono-ubiquitination is an essential step in DNA damage response. As FANCD2 interacts with BRCA1, is expressed in proliferating normal breast cells, and FANCD2 knockout mice develop breast tumors, we investigated the expression of FANCD2 in sporadic and hereditary invasive breast cancer patients to evaluate its possible role in breast carcinogenesis. Two tissue microarrays of 129 and 220 sporadic breast cancers and a tissue microarray containing 25 BRCA1 germline mutation-related invasive breast cancers were stained for FANCD2. Expression results were compared with several clinicopathological variables and tested for prognostic value. Eighteen of 96 (19%) sporadic breast cancers and two of 21 (10%) BRCA1-related breast cancers were completely FANCD2-negative, which, however, still showed proliferation. In the remaining cases, the percentage of FANCD2-expressing cells correlated strongly with mitotic index and percentage of cells positive for the proliferation markers Ki-67 and Cyclin A. In immunofluorescence double staining, coexpression of FANCD2 and Ki-67 was apparent. In survival analysis, high FANCD2 expression appeared to be prognostically unfavorable for overall survival (p = 0.03), independent from other major prognosticators (p = 0.026). In conclusion, FANCD2 expression is absent in 10–20% of sporadic and BRCA1-related breast cancers, indicating that somatic inactivating (epi)genetic events in FANCD2 may be important in both sporadic and hereditary breast carcinogenesis. FANCD2 is of independent prognostic value in sporadic breast cancer.

Joenje H, Patel KJ (2001) The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet 2:446–457PubMedCrossRef

D’Andrea AD, Grompe M (2003) The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 3:23–34PubMedCrossRef

Timmers C, Taniguchi T, Hejna J et al (2001) Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol Cell 7:241–248PubMedCrossRef

Strathdee CA, Gavish H, Shannon WR, Buchwald M (1992) Cloning of cDNAs for Fanconi’s anaemia by functional complementation. Nature 356:763–767PubMedCrossRef

de Winter JP, Waisfisz Q, Rooimans MA et al (1998) The Fanconi anaemia group G gene FANCG is identical with XRCC9. Nat Genet 20:281–283PubMedCrossRef

de Winter JP, Leveille F, van Berkel CG et al (2000) Isolation of a cDNA representing the Fanconi anemia complementation group E gene. Am J Hum Genet 67:1306–1308PubMed

de Winter JP, Rooimans MA, van Der Weel L et al (2000) The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nat Genet 24:15–16PubMedCrossRef

Lo Ten Foe JR, Rooimans MA, Bosnoyan-Collins L et al (1996) Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. Nat Genet 14:320–323PubMedCrossRef

Howlett NG, Taniguchi T, Olson S et al (2002) Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606–609PubMedCrossRef

10.

Garcia-Higuera I, Taniguchi T, Ganesan S et al (2001) Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 7:249–262PubMedCrossRef

11.

Waisfisz Q, de Winter JP, Kruyt FAE et al (1999) A physical complex of the Fanconi anemia proteins FANCG/XRCC9 and FANCA. Proc Natl Acad Sci USA 96:10320–10325PubMedCrossRef

12.

van de Vrugt HJ, Koomen M, Berns MAD et al (2002) Characterization, expression and complex formation of the murine Fanconi anaemia gene product FANCG. Genes Cells 7:333–342PubMedCrossRef

13.

Levitus M, Rooimans MA, Steltenpool J et al (2004) Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes. Blood 103:2498–2503PubMedCrossRef

14.

Meetei AR, Medhurst AL, Ling C et al (2005) A human ortholog of archael DNA repair protein Hef is defective in Fanconi anemia complementation group M. Nat Genet 37:958–963PubMedCrossRef

15.

Meetei AR, Levitus M, Xue Y et al (2004) X-linked inheritance of Fanconi anemia complementation group B. Nat Genet 36:1219–1224PubMedCrossRef

16.

Meetei AR, de Winter JP, Medhurst AL et al (2003) A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet 35:165–170PubMedCrossRef

17.

de Winter JP, van der Weel L, de Groot J et al (2000) The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANC and FANCG. Hum Mol Genet 9:2665–2674PubMedCrossRef

18.

Fei P, Yin J, Wang W (2005) New advances in the DNA damage response network of Fanconi anemia and BRCA proteins: FAAP95 replaces BRCA2 as the true FANCB protein. Cell Cycle 4:80–86PubMed

19.

Venkitaraman AR (2004) Tracing the network connecting BRCA and Fanconi anemia proteins. Nature 4:266–276

20.

Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, Lee EY (1999) BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res 59:3547–3551PubMed

21.

Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71PubMedCrossRef

22.

Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT (1995) Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9:444–450PubMedCrossRef

23.

Hölzel M, van Diest PJ, Bier P et al (2003) FANCD2 protein is expressed in proliferating cells of human tissues that are cancer-prone in Fanconi anemia. J Pathol 201:198–203PubMedCrossRef

24.

Houghtaling S, Timmers C, Noll M et al (2003) Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev 17:2021–2035PubMedCrossRef

25.

van der Groep P, Bouter A, van der Zanden R et al (2004) Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 96:712–713PubMed

26.

Packeisen J, Korsching E, Herbst H, Boecker W, Buerger H (2003) Demystified tissue microarray technology. Mol Pathol 56:198–204PubMedCrossRef

27.

Helms MW, Packeisen J, August C et al (2005) First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer. J Pathol 206:366–376PubMedCrossRef

28.

van Diest PJ (2002) No consent should be needed for using leftover body material for scientific purposes. For BMJ 325:648–651CrossRef

29.

Michalides R, van Tinteren H, Balkenende A et al (2002) Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer 86:402–408PubMedCrossRef

30.

Huisman A, Ploeger LS, Dullens HF, Poulin N, Grizzle WE, van Diest PJ (2005) Development of 3D chromatin texture analysis using confocal laser scanning microscopy. Cell Oncol 27:335–345PubMed

31.

van Diest PJ, Van der Wall E, Baak JPA (2004) Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 57:675–681PubMedCrossRef

32.

van Diest PJ, Baak JPA (1991) The morphometric Multivariate Prognostic Index (MPI) is the strongest prognosticator in premenopausal lymph node negative and lymph node positive breast cancer patients. Hum Pathol 22:326–330PubMedCrossRef

33.

Baak JP, van Diest PJ, Voorhorst FJ et al (2005) Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 23:5993–6001PubMedCrossRef

34.

Houghtaling S, Granville L, Akkari Y et al (2005) Heterozygosity for p53 (Trp53+/?) accelerates epithelial tumor formation in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Cancer Res 65:85–91PubMed

Title: Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer
Authors: Petra van der Groep
Michael Hoelzel
Horst Buerger
Hans Joenje
Johan P. de Winter
Paul J. van Diest
Publication date: 01-01-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9534-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

Dietary animal-derived iron and fat intake and breast cancer risk in the Shanghai Breast Cancer Study

Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1

Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation

Circulating endothelial progenitor cells correlate to stage in patients with invasive breast cancer

Long-term pattern of disease recurrence among patients with early-stage breast cancer according to estrogen receptor status and use of adjuvant tamoxifen

Activation of protein kinase A (PKA) signaling mitigates the antiproliferative and antiinvasive effects of α-difluoromethylornithine in breast cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer